portfolio
portfolio
The EU Malaria Fund aims to invest in at least 24 incorporated Malaria projects, as well as in 6 so-called "secondary exploitations" of these assets into different WHO priority diseases areas.
To date, the EU Malaria Fund has financed the following Malaria projects:
the portfolio
The EU Malaria fund works with a portfolio of promising projects. Compared to Oncology, TB or HIV, there are only very few companies active in the Malaria domain. Those originate from technology transfer out of many of Europe’s leading research organizations, and are not yet invested in by a large pharmaceutical company. Here, we prefer to fund platform projects, allowing for secondary exploitations of their anti-malaria assets, for example into COVID-19 and other important under-served infectious diseases.
This portfolio has been built as a result of an open call originally published on kENUP`s website for two years, and now available on this website. The current participants in the portfolio have been dedicated by the Scientific Advisory Council during its sessions held on March 4, 2019, June 20, 2019, April 22, 2020, August 26, 2020, and on December 18, 2020.
Being part of the fund’s portfolio grants companies the right to submit financing requests to the fund, following the fund’s operating procedures published in the Governance section of this website. Thus, companies included in the portfolio are not guaranteed to receive funding.
Other companies are expected to be added to the portfolio, if their malaria product provides a substantial additional opportunity, their entry lowers the risk of the portfolio, and the respective malaria asset has not yet been strategically invested by a large pharmaceutical company. Companies interested in working with the Fund should get in touch with the Secretariat of the Scientific Advisory Council
here.
companies in the portfolio
As of December 18, 2020, 17 companies with 30 independent projects have passed the Scientific Advisory Council's initial screening and are being invited to submit formal financing requests.
17 of these projects are vaccine candidates, vaccine-components or preventive mAbs, nine are novel therapeutics or therapeutic mAbs, three are diagnostics, and one project is in vector control.
The companies in the portfolio include AchilleS Vaccines
(part of the Siena vaccines hub), Deutsche Malaria GmbH
(with Tübingen University), Evotec SE
(licensed from Sanofi, under the joint - Evotec-led - infectious disease open innovation R&D platform), Global Access Diagnostics (with Mologic),Innovex Therapeutics S.L.
(with IS Global Barcelona), In2Care
(with Wageningen University & Research), Global Malaria Vaccines GmbH and OxYmmune Ltd., both spin-offs from Oxford University's
Jenner Institute
Laboratories, KELTICPharma
(with Glasgow University), Konica Minolta Austria
(with the University of Pretoria), Magnetrap (SA)
(with with Université de Mons and Université de Lyon 1), Sanaria, Inc., Serum Institute of India
(advised by Lion’s Head Global Partners), Sumaya Biotech
(with Heidelberg University), Takis Biotech S.r.l, (with Rottapharm Biotech S.r.l., IGEA S.p.A., and DPhar S.p.A.), VicuTec Biologicals GmbH
(with Max Planck Institute for Biophysical Chemistry and University Medical Center in Göttingen), as well as one confidential vaccine asset.
the pipeline
Additional projects are currently being reviewed according to the fund's operating procedures. They will eventually be presented to the Scientific Advisory Council. These projects include mAbs, other therapeutics, diagnostics and vaccines.
Companies interested in working with the fund should get in touch with the Secretariat of the Scientific Advisory Council
here.
